Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Luteolin vs Nano-luteolin in Tongue Squamous Cell Carcinoma Cell Lines
NCT03288298Phase 1Unknown
- Sponsor
- Cairo University
- Start
- Nov 2017
- Primary completion
- Sep 2018
- Modality
- Polymer-based Nanoparticles, Liposomes, Small Molecules
01
Overview
Phase 1, open-label trial of nano-luteolin in tongue squamous cell carcinoma (2 arms), sponsored by Cairo University. Primary endpoint: gene expression of Caspase 3 to detect apoptosis at 6 hours. Status: unknown.
02
Drugs
nano-luteolin
03
Conditions
tongue squamous cell carcinoma
Beyond the preview
Go deeper on NCT03288298.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03288298.